Reason for request
Inclusion on the list of medicines reimbursed by National Insurance and approved for use by hospitals in the ‘Central neuropathic pain in adults’ indication extension.
Clinical Benefit
| Substantial |
The actual benefit of LYRICA in the treatment of central neuropathic pain in adults is substantial. |
Clinical Added Value
| no clinical added value |
Lyrica does not provide any improvement in actual benefit (IAB level V) over the usual management of central neuropathic pain in adults. |
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
J1sUBgq28XjevY1G
Listen
